Download PDF
Semin Thromb Hemost 2014; 40(01): 034-040
DOI: 10.1055/s-0033-1363165
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Therapy for Thrombotic Thrombocytopenia Purpura: Past, Present, and Future

Kent Chapman
1   Department of Haematology, Pathology NSW, John Hunter Hospital, New South Wales, Australia
,
Sam Yuen
2   Department of Haematology, Calvary Mater Newcastle, New South Wales, Australia
› Author Affiliations
Further Information

Publication History

Publication Date:
31 December 2013 (online)

    Permissions and Reprints

Abstract

While clinical recognition of thrombotic thrombocytopenia purpura (TTP) has been evident for almost 90 years, the pathological basis of this disorder has only, relatively, recently been elucidated. Consequently, options for treating TTP had evolved rather slowly for many years. Despite this, current treatment practices of intensive plasma exchange often with immune modulation have seen survival rates increase dramatically. Nevertheless, the current understanding of TTP may witness the cusp of a new era for this disorder, with new and emerging treatments nearing clinical practice that specifically target the root cause of TTP. Some of these targeted approaches may even see the beginning of plasma-free treatments for TTP, with potentially faster recoveries and fewer long-term adverse effects.

Keywords

thrombotic thrombocytopenia purpura - TTP - therapy - von Willebrand cleaving protease - ADAMTS-13

Note

Since completing this review, a single report on the use of NAC in a case of TTP has recently emerged.[50] A 44-year-old woman presenting with clinical symptoms and laboratory results consistent with TTP was started on standard therapy including plasma exchange and corticosteroid treatment but remained largely unresponsive, and so rituximab was initiated. The patient's condition worsened and she became comatose; antibiotics were initiated, but cultures remained sterile. After 3 days of coma and further clinical deterioration, treatment with NAC was begun. The patient received a loading dose of 150 mg/kg NAC intravenously (IV) over 1 hour. Within 18 hours, the patient awakened abruptly and began communicating with medical personnel. Plasma exchange, corticosteroids, rituximab, and NAC infusion (150 mg/kg IV over 17 hr daily × 10 d) were continued and by day 17 the platelet count was more than 50 × 109/L. The patient fully recovered and was discharged on day 31.


 

  • References

  • 1 Moake JL, Rudy CK, Troll JH , et al. Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982; 307 (23) 1432-1435
    CrossrefPubMedGoogle Scholar
  • 2 Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996; 87 (10) 4235-4244
    CrossrefPubMedGoogle Scholar
  • 3 Furlan M, Robles R, Lämmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996; 87 (10) 4223-4234
    CrossrefPubMedGoogle Scholar
  • 4 Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339 (22) 1585-1594
    CrossrefPubMedGoogle Scholar
  • 5 Scheiflinger F, Knöbl P, Trattner B , et al. Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. Blood 2003; 102 (9) 3241-3243
    CrossrefPubMedGoogle Scholar
  • 6 Moschcowitz E. An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries: an undescribed disease. Arch Intern Med (Chic) 1925; 36 (1) 89-93
    CrossrefPubMedGoogle Scholar
  • 7 Tsai HM. Is severe deficiency of ADAMTS-13 specific for thrombotic thrombocytopenic purpura? Yes. J Thromb Haemost 2003; 1 (4) 625-631
    CrossrefPubMedGoogle Scholar
  • 8 Remuzzi G. Is ADAMTS-13 deficiency specific for thrombotic thrombocytopenic purpura? No. J Thromb Haemost 2003; 1 (4) 632-634
    CrossrefPubMedGoogle Scholar
  • 9 Amorosi EL, Ultmann JE. Thrombocytopic purpura: report of 16 cases and review of the literature. Medicine 1966; 45: 139-159
    CrossrefPubMedGoogle Scholar
  • 10 Burke HA, Hartman RC. Thrombotic thrombocytopenic purpura: Two patients with remission associated with use of large amount of steroids. Arch Intern Med 1959; 103: 105-112
    CrossrefPubMedGoogle Scholar
  • 11 Bernstock L, Hirson C. Thrombotic thrombocytopenic purpura. Remission on treatment with heparin. Lancet 1960; 1 (7114) 28-29
    PubMedGoogle Scholar
  • 12 Amir J, Krauss S. Treatment of thrombotic thrombocytopenic purpura with antiplatelet drugs. Blood 1973; 42 (1) 27-33
    CrossrefPubMedGoogle Scholar
  • 13 Cuttner J. Splenectomy, steroids, and dextran 70 in thrombotic thrombocytopenic purpura. JAMA 1974; 227 (4) 397-402
    CrossrefPubMedGoogle Scholar
  • 14 Kwaan HC, Guillermo G, Potter E, Stanzler R. The nature of the vascular lesion in thrombotic thrombocytopenic purpura. Ann Intern Med 1968; 68 (5) 1169-1170
    PubMedGoogle Scholar
  • 15 Bernard RP, Bauman AW, Schwartz SI. Splenectomy for thrombotic thrombocytopenic purpura. Ann Surg 1969; 169 (4) 616-624
    CrossrefPubMedGoogle Scholar
  • 16 Rubinstein MA, Kagan BM, MacGillviray MH, Merliss R, Sacks H. Unusual remission in a case of thrombotic thrombocytopenic purpura syndrome following fresh blood exchange transfusions. Ann Intern Med 1959; 51: 1409-1419
    CrossrefPubMedGoogle Scholar
  • 17 Bukowski RM, Hewlett JS, Harris JW , et al. Exchange transfusions in the treatment of thrombotic thrombocytopenic purpura. Semin Hematol 1976; 13 (3) 219-232
    PubMedGoogle Scholar
  • 18 Garthwaite T, Laurie A, Aster RH , et al. Remission in thrombotic thrombocytopenic purpura apparently induced by exchange transfusion. Clin Res 1976; 24: 570
    PubMedGoogle Scholar
  • 19 Bukowski RM, King JW, Hewlett JS. Plasmapheresis in the treatment of thrombotic thrombocytopenic purpura. Blood 1977; 50 (3) 413-417
    CrossrefPubMedGoogle Scholar
  • 20 Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 2001; 98 (6) 1662-1666
    CrossrefPubMedGoogle Scholar
  • 21 Sadler JE. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood 2008; 112 (1) 11-18
    CrossrefPubMedGoogle Scholar
  • 22 Zeigler ZR, Shadduck RK, Gryn JF , et al; North American TTP Group. Cryoprecipitate poor plasma does not improve early response in primary adult thrombotic thrombocytopenic purpura (TTP). J Clin Apher 2001; 16 (1) 19-22
    CrossrefPubMedGoogle Scholar
  • 23 Rock G, Anderson D, Clark W , et al; Canadian Apheresis Group; Canadian Association of Apheresis Nurses. Does cryosupernatant plasma improve outcome in thrombotic thrombocytopenic purpura? No answer yet. Br J Haematol 2005; 129 (1) 79-86
    CrossrefPubMedGoogle Scholar
  • 24 George JN, Gilcher RO, Smith JW, Chandler L, Duvall D, Ellis C. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: diagnosis and management. J Clin Apher 1998; 13 (3) 120-125
    CrossrefPubMedGoogle Scholar
  • 25 Nguyen L, Li X, Duvall D, Terrell DR, Vesely SK, George JN. Twice-daily plasma exchange for patients with refractory thrombotic thrombocytopenic purpura: the experience of the Oklahoma Registry, 1989 through 2006. Transfusion 2008; 48 (2) 349-357
    PubMedGoogle Scholar
  • 26 Scully M, Cohen H, Cavenagh J , et al. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol 2007; 136 (3) 451-461
    CrossrefPubMedGoogle Scholar
  • 27 Scully M, McDonald V, Cavenagh J , et al. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood 2011; 118 (7) 1746-1753
    CrossrefPubMedGoogle Scholar
  • 28 Allan DS, Kovacs MJ, Clark WF. Frequently relapsing thrombotic thrombocytopenic purpura treated with cytotoxic immunosuppressive therapy. Haematologica 2001; 86 (8) 844-850
    PubMedGoogle Scholar
  • 29 Beloncle F, Buffet M, Coindre JP , et al; Thrombotic Microangiopathies Reference Center. Splenectomy and/or cyclophosphamide as salvage therapies in thrombotic thrombocytopenic purpura: the French TMA Reference Center experience. Transfusion 2012; 52 (11) 2436-2444
    CrossrefPubMedGoogle Scholar
  • 30 Shortt J, Oh DH, Opat SS. ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura. N Engl J Med 2013; 368 (1) 90-92
    CrossrefPubMedGoogle Scholar
  • 31 Kremer Hovinga JA, Vesely SK, Terrell DR, Lämmle B, George JN. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 2010; 115 (8) 1500-1511 , quiz 1662
    CrossrefPubMedGoogle Scholar
  • 32 Shemin D, Briggs D, Greenan M. Complications of therapeutic plasma exchange: a prospective study of 1,727 procedures. J Clin Apher 2007; 22 (5) 270-276
    CrossrefPubMedGoogle Scholar
  • 33 Sutton DM, Nair RC, Rock G. Complications of plasma exchange. Transfusion 1989; 29 (2) 124-127
    CrossrefPubMedGoogle Scholar
  • 34 Basic-Jukic N, Kes P, Glavas-Boras S, Brunetta B, Bubic-Filipi L, Puretic Z. Complications of therapeutic plasma exchange: experience with 4857 treatments. Ther Apher Dial 2005; 9 (5) 391-395
    CrossrefPubMedGoogle Scholar
  • 35 Gibbs WW. Nanobodies. Sci Am 2005; 293 (2) 78-83
    PubMedGoogle Scholar
  • 36 Muyldermans S, Lauwereys M. Unique single-domain antigen binding fragments derived from naturally occurring camel heavy-chain antibodies. J Mol Recognit 1999; 12 (2) 131-140
    CrossrefPubMedGoogle Scholar
  • 37 Ewert S, Cambillau C, Conrath K, Plückthun A. Biophysical properties of camelid V(HH) domains compared to those of human V(H)3 domains. Biochemistry 2002; 41 (11) 3628-3636
    CrossrefPubMedGoogle Scholar
  • 38 Davies J, Riechmann L. Antibody VH domains as small recognition units. Biotechnology (N Y) 1995; 13 (5) 475-479
    CrossrefPubMedGoogle Scholar
  • 39 Lauwereys M, Arbabi Ghahroudi M, Desmyter A , et al. Potent enzyme inhibitors derived from dromedary heavy-chain antibodies. EMBO J 1998; 17 (13) 3512-3520
    CrossrefPubMedGoogle Scholar
  • 40 Callewaert F, Roodt J, Ulrichts H , et al. Evaluation of efficacy and safety of the anti-VWF Nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura. Blood 2012; 120 (17) 3603-3610
    CrossrefPubMedGoogle Scholar
  • 41 Duby C . (Ablynx). Do Nanobodies belong to biologicals and how should they be developed in early drug development?. Presented at the Belgian Pharmaceutical Conference; April 22, 2013; Dolce La Hulpe, Brussels
    PubMedGoogle Scholar
  • 42 Shigdar S, Luczo J, Wei MQ , et al. Aptamer Therapeutics: The 21st Century's Magic Bullet of Nanomedicine. Open Conference Proc J 2010; 1: 118-124
    PubMedGoogle Scholar
  • 43 Gilbert JC, DeFeo-Fraulini T, Hutabarat RM , et al. First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation 2007; 116 (23) 2678-2686
    CrossrefPubMedGoogle Scholar
  • 44 Knöbl P, Jilma B, Gilbert JC, Hutabarat RM, Wagner PG, Jilma-Stohlawetz P. Anti-von Willebrand factor aptamer ARC1779 for refractory thrombotic thrombocytopenic purpura. Transfusion 2009; 49 (10) 2181-2185
    CrossrefPubMedGoogle Scholar
  • 45 Samuni Y, Goldstein S, Dean OM, Berk M. The chemistry and biological activities of N-acetylcysteine. Biochim Biophys Acta 2013; 1830 (8) 4117-4129
    CrossrefPubMedGoogle Scholar
  • 46 Chen J, Reheman A, Gushiken FC , et al. N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice. J Clin Invest 2011; 121 (2) 593-603
    CrossrefPubMedGoogle Scholar
  • 47 Turner N, Nolasco L, Moake J. Generation and breakdown of soluble ultralarge von Willebrand factor multimers. Semin Thromb Hemost 2012; 38 (1) 38-46
    Article in Thieme ConnectPubMedGoogle Scholar
  • 48 Favaloro EJ, Bonar R, Chapman K, Meiring M, Funk Adcock D. Differential sensitivity of von Willebrand factor (VWF) 'activity' assays to large and small VWF molecular weight forms: a cross-laboratory study comparing ristocetin cofactor, collagen-binding and mAb-based assays. J Thromb Haemost 2012; 10 (6) 1043-1054
    CrossrefPubMedGoogle Scholar
  • 49 N-acetylcysteine in TTP. U.S. National Institutes of Health http://clinicaltrials.gov/show/NCT01808521 . Accessed July 12, 2013
    PubMed
  • 50 Li GW, Rambally S, Kamboj J, Reilly S, Moake JL, Udden MM, Mims MP. Treatment of refractory thrombotic thrombocytopenic purpura with N-acetylcysteine: a case report (epub ahead of print). Transfusion 2013; ; doi: 10.1111/trf.12440
    PubMedGoogle Scholar